Lee Chul-Kyu, Lee Sang Ryul, Cho Jin Mo, Yang Kyung Ah, Kim Se-Hyuk
Department of Neurosurgery, Gamma Knife Center, Ajou University School of Medicine, Suwon, Korea.
J Korean Neurosurg Soc. 2011 Sep;50(3):179-84. doi: 10.3340/jkns.2011.50.3.179. Epub 2011 Sep 30.
The aim of this study is to evaluate the therapeutic effects of gamma knife radiosurgery (GKRS) in patients with multiple brain metastases and to investigate prognostic factors related to treatment outcome.
We retrospectively reviewed clinico-radiological and dosimetric data of 36 patients with 4-14 brain metastases who underwent GKRS for 264 lesions between August 2008 and April 2011. The most common primary tumor site was the lung (n=22), followed by breast (n=7). At GKRS, the median Karnofsky performance scale score was 90 and the mean tumor volume was 1.2 cc (0.002-12.6). The mean prescription dose of 17.8 Gy was delivered to the mean 61.1% isodose line. Among 264 metastases, 175 lesions were assessed for treatment response by at least one imaging follow-up.
The overall median survival after GKRS was 9.1±1.7 months. Among various factors, primary tumor control was a significant prognostic factor (11.1±1.3 months vs. 3.3±2.4 months, p=0.031). The calculated local tumor control rate at 6 and 9 months after GKRS were 87.9% and 84.2%, respectively. Paddick's conformity index (>0.75) was significantly related to local tumor control. The actuarial peritumoral edema reduction rate was 22.4% at 6 months.
According to our results, GKRS can provide beneficial effect for the patients with multiple (4 or more) brain metastases, when systemic cancer is controlled. And, careful dosimetry is essential for local tumor control. Therefore, GKRS can be considered as one of the treatment modalities for multiple brain metastase.
本研究旨在评估伽玛刀放射外科治疗(GKRS)对多发脑转移瘤患者的疗效,并探讨与治疗结果相关的预后因素。
我们回顾性分析了2008年8月至2011年4月期间接受GKRS治疗264个病灶的36例有4 - 14个脑转移瘤患者的临床放射学和剂量学数据。最常见的原发肿瘤部位是肺(n = 22),其次是乳腺(n = 7)。在进行GKRS时,卡诺夫斯基功能状态评分中位数为90,平均肿瘤体积为1.2立方厘米(0.002 - 12.6)。平均17.8 Gy的处方剂量给予平均61.1%等剂量线。在264个转移瘤中,175个病灶通过至少一次影像学随访评估治疗反应。
GKRS后的总体中位生存期为9.1±1.7个月。在各种因素中,原发肿瘤控制是一个重要的预后因素(11.1±1.3个月对3.3±2.4个月,p = 0.031)。GKRS后6个月和9个月计算的局部肿瘤控制率分别为87.9%和84.2%。帕迪克适形指数(>0.75)与局部肿瘤控制显著相关。6个月时肿瘤周围水肿的精算减轻率为22.4%。
根据我们的结果,当全身癌症得到控制时,GKRS可为多发(4个或更多)脑转移瘤患者提供有益效果。而且,仔细的剂量学对于局部肿瘤控制至关重要。因此,GKRS可被视为多发脑转移瘤的治疗方式之一。